在帕金森病中抑制蛋白酶激活受体-2激活使用1 - 皮皮里丁 propionic 酸
Santina Quarta1, Michele Sandre2, Mariagrazia Ruvoletto1
1Department of Medicine, University of Padova, 35122 Padova, Italy.
Biomedicines
|July 27, 2024
概括
1-Piperidin Propionic Acid (1-PPA) 在帕金森病模型中降低神经炎症和粉样蛋白聚合物. 这种新型的蛋白酶激活受体-2 (PAR2) 抑制剂显示出控制神经炎症的潜力.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经炎症在帕金森病 (PD) 中起着双重作用,导致神经元损伤.
- 微质激活和蛋白酶激活受体-2 (PAR2) 信号传递在PD神经炎症中至关重要.
- 反应性星体细胞,由微质细胞触发,可以促进神经元的破坏.
研究的目的:
- 为了研究1-Piperidin Propionic Acid (1-PPA),一种新的 PAR2 抑制剂在帕金森病中的治疗潜力.
- 评估1-PPA对神经炎症和PD中的微质激活的影响.
- 在PD模型中评估1-PPA对粉样蛋白聚合物和PAR2表达的影响.
主要方法:
- 来自PD患者的培养人体纤维细胞被用1-PPA治疗,并使用Thioflavin S测定和免疫光检测分析了粉样蛋白聚合物和PAR2表达.
- 评估了PAR2的转录和蛋白质水平.
- 用LPS激活的小鼠微质细胞接受了1-PPA治疗,以分析炎症标志物 (IL-1β,IL-6,TNF-α) 和PAR2表达.
主要成果:
- 1-PPA治疗显著降低了PD患者纤维细胞中的粉样蛋白聚合物.
- 在1-PPA治疗后观察到PAR2的转录和蛋白质水平显著下降.
- 在小鼠微质细胞中,1-PPA显著降低了炎症标志物和PAR2表达的调节.
结论:
- 在帕金森病的实验模型中,1-PPA有效降低神经炎症和粉样蛋白聚合物的形成.
- 使用1-PPA对PAR2进行药理抑制是治疗PD中神经炎症的一个有希望的策略.
- 准PAR2为帕金森病治疗提供了一个潜在的新疗法途径.
更多相关视频
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
7.5K
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
7.5K
相关概念视频
01:24Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
01:15Parkinson's Disease: Overview
510
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
510
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
549
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
549
01:21Antipsychotic Drugs: Typical and Atypical Agents
164
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
164